A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer); 2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures; 3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed; 4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Study Type
OBSERVATIONAL
Enrollment
500
No intervention
Sichuan Cancer Hospital
Chengdu, China
RECRUITINGProgress Freesurvival (PFS)
The time from the start of treatment until the patient progresses further or dies.
Time frame: Average six months after study completion.
Overall Survival (OS)
Measure the time from the start of treatment to the time of death.
Time frame: Average six months after study completion.
Occurrence of adverse reactions
All adverse events were recorded.
Time frame: Average six months after study completion.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.